| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.11. | Sanuwave outlines 2027 97610 payment of $314.54 amid pivot to hospital pressure injury market | 1 | Seeking Alpha | ||
| SANUWAVE HEALTH Aktie jetzt für 0€ handeln | |||||
| 11.11. | Sanuwave Q3 2026 slides show 24% revenue drop, system sales plunge | 3 | Investing.com | ||
| 11.11. | SANUWAVE Health Q3 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| 11.11. | SANUWAVE Health GAAP EPS of -$0.16, revenue of $8.58M | 1 | Seeking Alpha | ||
| 10.11. | Sanuwave Health, Inc.: Sanuwave Announces Q3 FY2026 Financial Results | 1 | GlobeNewswire (USA) | ||
| 10.11. | SANUWAVE Health, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.11. | SANUWAVE Health, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Sanuwave Health, Inc.: Sanuwave Health Comments on 2027 Medicare Physician Fee Schedule Rate for Ultramist | 1 | GlobeNewswire (USA) | ||
| 28.10. | SANUWAVE Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.09. | Sanuwave Health verstößt gegen Nasdaq-Börsenregeln: Marktkapitalisierung zu gering | 3 | Investing.com Deutsch | ||
| 25.09. | SANUWAVE Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.08. | Sanuwave withdraws FY2026 revenue guidance amid CMS proposal implying 97610 reimbursement of $316.59 in 2027 | 16 | Seeking Alpha | ||
| 07.08. | Sanuwave Q2 2026 slides: consumables rise as system sales slide | 1 | Investing.com | ||
| 07.08. | SANUWAVE Health GAAP EPS of -$0.08, revenue of $9.74M | 1 | Seeking Alpha | ||
| 06.08. | SANUWAVE Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.08. | SANUWAVE Health, Inc.: Sanuwave Announces Q2 FY2026 Financial Results | 228 | GlobeNewswire (Europe) | Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026... ► Artikel lesen | |
| 06.08. | SANUWAVE Health, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.07. | Sanuwave sees Q2 revenue up to $9.8M | 1 | Seeking Alpha | ||
| 13.07. | Sanuwave: Q2-Umsatz übertrifft Prognose | 3 | Investing.com Deutsch | ||
| 13.07. | Sanuwave posts Q2 revenue of $9.6M-$9.8M, beating guidance | 1 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 6,986 | -1,77 % | Truist raises Teladoc stock price target to $9 on EBITDA outlook | ||
| SERNOVA BIOTHERAPEUTICS | 0,059 | 0,00 % | Sernova Biotherapeutics: 11,2 Millionen Dollar für die Fusion - und doch rutscht die Aktie | ||
| CERENOME | 0,541 | -7,52 % | Cerenome outlines $10M-$12.5M 2026 gross billings run rate exit while targeting mid-2027 REYOBIQ top line data | ||
| ATOSSA THERAPEUTICS | 1,570 | -2,48 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Rekord bei Umsatz und Gewinn - lächerliche Bewertung! | Sonoma Pharmaceuticals macht den nächsten gewaltigen Schritt auf dem Weg zum profitablen Wachstumsunternehmen. Nach dem erstmaligen Erreichen eines positiven EBITDA im Vorquartal meldet der Healthcare-Spezialist... ► Artikel lesen | |
| TANDEM DIABETES | 15,500 | +0,65 % | Warum die Aktie von Tandem Diabetes Care heute kräftig zulegt | ||
| CO-DIAGNOSTICS | 0,134 | -18,59 % | Co-Diagnostics Announces Reverse Stock Split | SALT LAKE CITY, Nov. 19, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Diagnostics" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development... ► Artikel lesen | |
| QUIDELORTHO | 7,790 | -4,09 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,120 | +0,47 % | Veru presents data on enobosarm for obesity treatment | ||
| LIFEWARD | 2,960 | +1,02 % | Lifeward GAAP EPS of -$1.32 misses by $0.50, revenue of $5.43M misses by $1.81M | ||
| CLOVER HEALTH INVESTMENTS | 3,470 | +1,17 % | CLOVER HEALTH INVESTMENTS, CORP. /DE - 8-K, Current Report | ||
| SENSEONICS | 8,800 | +8,64 % | Beta Bionics, Inc.: Senseonics and Beta Bionics Launch Eversense 365 and iLet Bionic Pancreas Integration | ||
| TEMPEST THERAPEUTICS | 0,295 | -3,73 % | Tempest Therapeutics: Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update | ||
| NANO-X IMAGING | 0,230 | -0,04 % | NANO-X IMAGING LTD: Nanox to Showcase Its Innovative Technology and Advances Across Nanox.ARC X and Nanox.AI at RSNA 2026 | ||
| IMUNON | 0,416 | +4,00 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen |